Cargando…
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136869/ https://www.ncbi.nlm.nih.gov/pubmed/32247642 http://dx.doi.org/10.1016/j.annonc.2020.03.300 |
| _version_ | 1783518331103346688 |
|---|---|
| author | Michot, J.-M. Albiges, L. Chaput, N. Saada, V. Pommeret, F. Griscelli, F. Balleyguier, C. Besse, B. Marabelle, A. Netzer, F. Merad, M. Robert, C. Barlesi, F. Gachot, B. Stoclin, A. |
| author_facet | Michot, J.-M. Albiges, L. Chaput, N. Saada, V. Pommeret, F. Griscelli, F. Balleyguier, C. Besse, B. Marabelle, A. Netzer, F. Merad, M. Robert, C. Barlesi, F. Gachot, B. Stoclin, A. |
| author_sort | Michot, J.-M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7136869 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71368692020-04-07 Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report Michot, J.-M. Albiges, L. Chaput, N. Saada, V. Pommeret, F. Griscelli, F. Balleyguier, C. Besse, B. Marabelle, A. Netzer, F. Merad, M. Robert, C. Barlesi, F. Gachot, B. Stoclin, A. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2020-07 2020-04-02 /pmc/articles/PMC7136869/ /pubmed/32247642 http://dx.doi.org/10.1016/j.annonc.2020.03.300 Text en © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Michot, J.-M. Albiges, L. Chaput, N. Saada, V. Pommeret, F. Griscelli, F. Balleyguier, C. Besse, B. Marabelle, A. Netzer, F. Merad, M. Robert, C. Barlesi, F. Gachot, B. Stoclin, A. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report |
| title | Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report |
| title_full | Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report |
| title_fullStr | Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report |
| title_full_unstemmed | Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report |
| title_short | Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report |
| title_sort | tocilizumab, an anti-il-6 receptor antibody, to treat covid-19-related respiratory failure: a case report |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136869/ https://www.ncbi.nlm.nih.gov/pubmed/32247642 http://dx.doi.org/10.1016/j.annonc.2020.03.300 |
| work_keys_str_mv | AT michotjm tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT albigesl tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT chaputn tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT saadav tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT pommeretf tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT griscellif tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT balleyguierc tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT besseb tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT marabellea tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT netzerf tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT meradm tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT robertc tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT barlesif tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT gachotb tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport AT stoclina tocilizumabanantiil6receptorantibodytotreatcovid19relatedrespiratoryfailureacasereport |